| 000 | 00920 a2200289 4500 | ||
|---|---|---|---|
| 005 | 20250513233301.0 | ||
| 264 | 0 | _c20010412 | |
| 008 | 200104s 0 0 eng d | ||
| 022 | _a1464-8431 | ||
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aKamb, A | |
| 245 | 0 | 0 |
_aTransdominant genetics, peptide inhibitors and drug targets. _h[electronic resource] |
| 260 |
_bCurrent opinion in molecular therapeutics _cDec 2000 |
||
| 300 |
_a662-9 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 | _aDrug Design |
| 650 | 0 | 4 |
_aGenes, Dominant _xdrug effects |
| 650 | 0 | 4 | _aGenetic Techniques |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aModels, Molecular |
| 650 | 0 | 4 |
_aPeptides _xchemistry |
| 650 | 0 | 4 | _aPhenotype |
| 650 | 0 | 4 |
_aProteins _xantagonists & inhibitors |
| 700 | 1 | _aTeng, D H | |
| 773 | 0 |
_tCurrent opinion in molecular therapeutics _gvol. 2 _gno. 6 _gp. 662-9 |
|
| 999 |
_c11186577 _d11186577 |
||